WPCE ~i+|x4q!=q1Y-bӂ5mr"0' zx" @>:v_<^I;ZPy\ӡ$vf+;A7)g_D3x˽}A$+tNP71T4$PHf! luHcuWgh uR2> 0`c?c? 0?? 0`@`@ 1u%A%A%A%A BAAAA6AAAAAAAAAAAA 72BB/CC 1NCNCNCNCNCNCNCNCNCNCNCNCNCNCNCNCNCNCNCNCNCU:CCCCM)D B-D-D-DVJD&d9 Z6Times New Roman RegularX( Z$ IS , .\R6&A4\XħXXXTRW<6&A4W<6&A4 6&A4 6&A4T ? XXħ0?vvbX0#ggdd  8dXXd8ISUS.,    \\clust02\ps_pdf_prentuntt0 W:\WP2000\template\SKJRI~3H.WPTUW:\WP2000\template\SkjritunY2k.wptMMMEEEM2s ^2\W31\a03|x*+ (_2623  ..*D+J (_25   ," <DL,23  ..  2( 4 <DL2  *A+J (_24   ) <DL)23  ..  2( 4 <DL2  *>+J (_23  ` &<<DL&23  ..  2( 4 <DL2  *;+J (_22   #DL#23  ..  2( 4 <DL2  *8+J (_21    DL 23  ..  2( 4 <DL2  *5+J (_20  h DDL23  ..  2( 4 <DL2  *2+J (_19   L23  ..  2( 4 <DL2  */+J (_18    L23  ..  2( 4 <DL2  * (_1723  Ԁ*DJ (_16   ," <DL,23  Ԁ  2( 4 <DL2  *AJ (_15   ) <DL)23  Ԁ  2( 4 <DL2  *>J (_14  ` &<<DL&23  Ԁ  2( 4 <DL2  *;J (_13   #DL#23  Ԁ  2( 4 <DL2  *8J (_12    DL 23  Ԁ  2( 4 <DL2  *5J (_11  h DDL23  Ԁ  2( 4 <DL2  *2J (_10   L23  Ԁ  2( 4 <DL2  (/J &_9    L23  Ԁ  2( 4 <DL2  ( &_823  (DJ &_7   ," <DL,23   2( 4 <DL2  (AJ &_6   ) <DL)23   2( 4 <DL2  (>J &_5  ` &<<DL&23   2( 4 <DL2  (;J &_4   #DL#23   2( 4 <DL2  (8J &_3    DL 23   2( 4 <DL2  (5J &_2  h DDL23   2( 4 <DL2  (2J &_1   L23   2( 4 <DL2  &/J $_    L23   2( 4 <DL2  [[d..% %d  -$ISUS.,,,..XXXX? ,LXX0?vvbX0#ggdd  ISIS,.      1    _V ,LԀ_International_Ԁ_Narcotics_Ԁ_Control_Ԁ_Board_Ԁ2004;_Psychotropic_Ԁ_Substances_;_Statistics_Ԁfor2003;_Assess  ment_Ԁof_Annual_Ԁ_Medical_Ԁ_and_Ԁ_Scientific_Ԁ_Requiremnets_,SameinuWuYj;Wirnar,NewYork2005.#,L VW#()(3$ Z!ISUS.,,,..TRV<6&A4V<6&A4 6&A4 6&A4TXXXXTRV<6&A4V<6&A4 6&A4 6&A4T ? 9XX0?vvbX0#ggdd  8Mdd8ISIS,.         1  (%$  1  uuuu'dxdSheet1  0 a'ISUS.,,,..XXXX? ,LXX0?vvbX0#ggdd  ISIS,.   _Ԁ<Dash-Dot-Dotd000000Dash-Dotd000)Hairline d&0 d d( (dd0ikmo %Eu{}1. a. 1.StafliWir undir t?luliW1.a.1.()3$ Z!ISUS.,,,..TRV<6&A4X3' Letter 6&A43'TXXXXTRV<6&A4V<6&A4 6&A4 6&A4T ? 9XX0?vvbX0#ggdd  8Mdd8ISIS,.     ()3$ Z!ISUS.,,,..TRV<6&A4X3' Letter 6&A43'TXXXXTRV<6&A4V<6&A4 6&A4 6&A4T ? 9XX0?vvbX0#ggdd  8Mdd8ISIS,.     (53$ Z!ISUS.,,,..TRV<6&A4X3' Letter 6&A43'TXXXXTRV<6&A4V<6&A4 6&A4 6&A4T ? 9XX0?vvbX0#ggdd  8Mdd8ISIS,.      d (M0J$2  0  .3  0 ` (8+$0  2%3  0`  " "(u$0  0` (#(#` `  2  a  .3  0` (#` (#(`$0  0` (#(#0 ` (#` (#0 (# (#"h2  0  .3  0(#(#3#37=CIQYag1.a.i.(1)(a)(i)1)a) d , g+ISUS.,,,..XXXX? ,LXX0?vvbX0#ggdd  ISIS,.   d  ݀qi) %y_ gEu{}a. 1. a.T?luliWur undir stafliWa.1.a.1)a)4cp Z "Times Regular[ [d L e)ISUS.,,,..XXXX? ,LXX0?vvbX0#ggdd  ISIS,.   _>? Ҁ Z!ISUS.,,,..TRW<6&A4X3' Letter 6&A43'TXXXXTRW<6&A4W<6&A4 6&A4 6&A4T ? ,LXX0?vvbX0#ggdd  8dd8ISIS,.     _ >?  _ikmo(%03q9 9131.lggjafarYing2004!2005. ( Xskj.1237"671.ml.     `,L@"Svar#,L `#   heilbrigWisrWherraviWfyrirspurnstuR.J;hannesd;tturum_lyfjanotkun_Ԁbarna.     Fyrirspurninhlj;Warsvo: K #  "i0J"  i0J2%  1  .3  Ԉ0    HvernigskUrirrWherrast;rauknanotkun_geWlyfja_ԀviW_athyglisbresti_Ԁog_ofvirkni_Ԁhj    brnum?i0J݌   Ќ  "i0J"  i0J2%  2  .3  Ԉ0    TelurrWherraeWlilegtaWannaWYsundbarnaaldrinum1!14ra,Y.e.um2%   barnaYeimaldri,takiYessilyfaWstaWaldri?i0J݌wO  Ќ  "i0J"  i0J- 2%  3  .3  Ԉ0    HyggstrWherrabregWastviWYessueinhvernhtt?i0J- Z ݌B  Ќ    1._Athyglisbrestur_ԀmeW_ofvirkni_Ԁ(_AMO_)erYUWingenskahugtakinu_Attention_Ԁ_Deficit_/   _Hyperactivity_Ԁ_Disorder_Ԁ(_ADHD_)semvsartilsjkd;mssemranns;knirbendatilaWeigisr {  _meinafrWilegar_Ԁrturheila.Sjkd;murinner_erfanlegur_,semm.a.kemurframrann nF s;knum_eineggja_ԀtvburumsemalastuppviWmismunandiaWstWur.Sjkd;murinneroftast 9 greindurforsk;laaldri.TaliWeraWum2!5%barnahafisjkd;minn,enhannerYrisvartil  fj;rumsinnumalgengarihjdrengjum.Hjum30%barnannahaldaeinkenniframfram  fullorWinsrYeimmliaWYaWveldurverulegumtruflunumvenjulegulfi. r   UmtalsverWaukninghefurorWiWnotkun_methylphenidats_ԀviW_athyglisbresti_ԀmeW_ofvirkni_ e= undanfrnumrumogennmeiriaukningkostnaWisamkvmtupplUsingumfr 0 Tryggingastofnunrkisins.    Tafla1.Fjldi_DDD_Ԁogtgjld_TR_,2002!2004.  i ,L*,2d dd Xdd Xdd X>>," ,] ,] ,] ,] ,] ,] +   =Q0\4\4  = =Q0ii  = LQ?'\4 Q  L LQ?'i Q  L @  Fjldi_DDD_ OQB*\4" Q  O OQB*i" Q  O @ _Lyfjatgjld_Ԁ_TR_ gQV5\4"   Q Fg gQV5i"   Q Fg_Aldursbil_ LQ;'' Q L LQ;'\4Q L2002 LQ;''!3Q L LQ;'\4 3Q L2003 LQ;''"3Q L LQ;'\4!3Q L2004 LQ;''#3Q L LQ;'\4"3Q L2002 LQ;''$3Q L LQ;'\4#3Q L2003 LQ;''%3Q L LQ;'\4$3Q L2004 ]S2'&3 F Q <] ]S2\4%3 F Q <]0-19ra E;'' E E;''& E267.050 E;'(3 E E;'''3 E373.298 E;')3 E E;''(3 E487.633 E;'*3 E E;'')3 E16.584.785 E;'+3 E E;''*3 E63.825.079 E;',3 E E;''+3 E112.678.616 ]S2-3 <  F] ]S2',3 <  F]>19ra E;'. E E;'- E109.334 E;'/3 E E;'.3 E145.699 E;'03 E E;'/3 E175.250 E;'13 E E;'03 E6.305.135 E;'23 E E;'13 E13.701.437 E;'33 E E;'23 E16.178.672 XN243 F  X XN233 F  XSamtals E;'`5 E E;'4 E376.384 E;'`63 E E;'53 E518.998 E;'`73 E E;'63 E662.883 E;'`83 E E;'73 E22.889.920 E;'`93 E E;'83 E77.526.516 E;'`:3 E E;'93 E128.857.288 XN-`;3  FX XN-:3  FX  E;'S+< E E;'`; E E;'S+= E E;'`< E E;'S+> E E;'`= E E;'S+? E E;'`> E E;'S+@ E E;'`? E E;'S+A E E;'`@ E ]S2S+B F  ] ]S2`A F  ] Aukningfrfyrrari E;'C E E;'S+B E E;'D" E E;'S+C" E142.614 E;'E3 E E;'S+D3 E143.885 E;'F3 E E;'S+E3 E E;'G3 E E;'S+F3 E54.636.596 E;'H3 E E;'S+G3 E51.330.772 dQS2I3   d dQS2S+H3   dHlutfallslegaukning @Q/'JQ @ @Q/'IQ @ CQ2KQ C CQ2JQ C38% LQ;'L3Q L LQ;'K3Q L28% @Q/'M3Q @ :Q)'L3Q : CQ2NQ C CQ2MQ C239% LQ;'O3Q L LQ;'N3Q L66%B86P3   Q B,L   SamkvmtupplUsingumfr_Eftirlitsstofnun_ԀSameinuWuYj;WannameW_vana_-og_fkni !WQ efnum_Ԁ(_INCB_)+ .%  1      ׀varnotkun_methylphenidats_Ԁhvergimeirien0slandiriW2003.XaWr J""R mldistnotkunin5,27_DDD_Ԁ(skilgreindir_dagskammtar_)1.000baoghafWiYaukist #S grWarlegafrrinu1999Yegarnotkuninmldist1,21_DDD_._Nstmesta_Ԁnotkuninvar #T BandarkjunumriW2003,eWa5,21_DDD_ԀenYarlandivarnotkuninhinsvegarmest $ U heiminumriW1999,eWa4,32_DDD_.0norrnumsamanburWihafWi0slandalgjrasrstWu v%N!V 9 y_   riW2003enYvarnotkunin0,40DDDDanmrku,0,29DDDFinnlandi,2,13DDD - Noregiog0,35DDDSvYj;W.SamkvmtupplUsingumfrINCBvarum70%afheildar  notkunmethylpheniadtsheiminumBandarkjunumriW2003.Samkvmtsmuheimild  hafahyggjurvaknaWBandarkjunumvegnahugsanlegraofgreiningaAMO_athyglisbresti_ԀmeW a _ofvirkni_ogofnotkunarmethylphenidatssemaWallegaerYartalinstafaaf_auglUsingaherferW Y, um_Ԁsemm.a.hafabeinstbeintaWsjklingumogalmenningi. $   EinsogframkemurtflunnihraWframanhefurkostnaWurundanfrnumrumvaxiW  umtalsvertumframYaWsemnotkuninsegirtilum.stWanerrakintilYessaWmiWjuri   2003kommarkaWinnnUttlangvirktformmethylphenidatssemvarmundUraraenYaWsem  X fyrirvarennotkuninfrWistaWmestuyfirYaWform,aukYesssemhnj;ksttilmuna. P #  Langvirkmethylphenydatlyf(RitalinUno,Concerta)erutalinhafa;tvrWakostiumfram    Ritaln,annarsvegarvegnaYessaWYaulyfYarfekkiaWtakanemaeinusinnidagoghins    vegarvegnaYessaWtaliWeraWYaWsmunerfiWaraaWmisnotaYau,YarsemumforWatflur   eraWrWa.FklarskjastYvmunsWurnUjulyfin.WurkvrtuWukennararoftyfirYvaW |O  brnintkjumeWsrlyfsk;lann,enYesserekkitalinYrflengurmeWhinumnUjuforWa G  lyfjum.XettakannaWhafavaldiWeinhverriaukninguheildarnotkunafmethylphenydati,   aukYesssem;ttilknaviWaWeinhverumhverfibarnsinskynniaWmisnotalyfiWhefure.t.v.   minnkaWviWYetta. {    HrlandihefurenginknnunveriWgerWYvhvortumofgreiningarAMO_athyglisbresti_ sF meW_ofvirkni_eWaofnotkunmethylphenidatssaWrWaeWahvortauglUsingarlyfjafyrirtkja > hafa;eWlileghrifnotkunina.     Ranns;knirsembendatilgagnsemilyfjameWferWarinnarerutaldarafgerandiogmtelja  lklegtaWYaWshelstaorskaukningarnotkunlyfsins,a.m.k.aWYvgefnuaWekkirWi r nnursj;narmiWenfagleglyfjavsunum. j=   2.HegWunbarnannaereinagreiningartkiWsemhgteraWnota.Ranns;knirsUnaaW  erfiWarheimilisaWstWureWauppeldisskilyrWivaldaekkisjkd;mnum.UmeraWrWaalvar  legansjkd;m,ekkiminnihttarhegWunarvandaml.Hanngreinistoftastumforsk;laaldur. i Helstueinkennieruofvirkni,hvatvsiogathyglisbrestur,enmismunandierhjeinstaklingum a4 hvaWaeinkennierumestberandi. ,   HrlandieruYaWnnasteingngubarna-ogunglingageWlknarogrfirbarnalknar  meWsrfrWirttindiYrngumsrsviWum,svosemtaugalkningumbarnaogYroskarskun  umbarna,semhefjaslkalyfjameWferW.HeimilislknarskrifahinsvegaroftupplyfiWeftir `  aWgreininghefurveriWgerWogmeWferWinhafin. X+!   3.XegarfjallaWerumvandaYeirrabarnaogunglingasemeigaviWgeWrnvandamlaW # strWaverWuraWhafahugaaWlyfjameWferWeraWeinseinYeirraleiWaertilgreinakoma.MeW  $ YaWhugaaWtryggjaaWgangYessah;psaWsemfjlbreyttastriheilbrigWisYj;nustuogstuWn !W% ingihafaframlgtilYessamlaflokksveriWst;raukinundanfrnumrum. O""& Ѐ  VeriWeraWgeratilraunirmeWauknaYj;nustuinnanheilsugslunnar,ogerubundnar #' vonirviWaWrangursrktreynistaWtakastviWgeWraskanirmeWYverfagleguteymiheilsu #( gslunni. $ )   Verkefnisstj;rivarrWinntilheilbrigWis-ogtryggingamlarWuneytisinstilYessaWgera {%N!* tillgurumsamYttinguYj;nustukerfasemYj;naYessumeinstaklingum. F&"+   NefnderstarfandisemmunvntanlegaskilarWherratillgumnvor,enhnskoWar '", m.a.hvernigbestmegitryggjaYessaYj;nustulandsbyggWinni. '#-   XerveriWaWendurskoWask;lahjkrunogmiWstWfyrirYYj;nustuernHeilsu - verndarstWinni.    KvartanirberastmjgsjaldantillandlknisembttisinsvegnalyfjameWferWarviW  ofvirkni.LandlknirhefurenguaWsWurhaldiWfundimeWbarna-ogunglingageWlknum a tilaWrWasrstakleganotkunmethylphenidats.0samrWiviWbarna-ogunglingageWlkna Y, ertluninaWskipastarfsh;pnstunnitilYessaWgeraklnskarleiWbeiningarfyrirmeW $ hndlunAMO_athygsllissberstrests_ԀmeW_ofvirkni_ԀmeWlkumhttioggerWarhafaveriWfyrirUmsaaWra  meWferW.XrmunustyWjastviWvntanlegarleiWbeiningarfrNationalInstituteofClinical   Excellence(NICE)Bretlandi,enmargarklnskarleiWbeiningarummeWferWannarra  X sjkd;mahrlandihafabyggstleiWbeiningumfrYeirristofnun.LeiWbeiningarNICE P #  varWandiathyglisbrestmeWofvirknikomusWasttriW2000ennUjarleiWbeiningareru    vntanlegarinnanfrramnaWa.      hyggjurfyrirspyrjandansafaukninguYessaraumrddulyfjaundanfrnumrumeru   skiljanlegarogertekiWundirYr. |O    RWherramun;skaeftirYvviWlandlkniogMiWstWheilsuverndarbarnaaWskoWa G  breiWarigrundvellisamrWiviWslfrWiYj;nustusk;laogflagsYj;nustusveitarflaga   hvernigbestverWibrugWistviWYeirrimikluaukninguathyglisbrestiogofvirknibarnasem   hrvirWisthafattsrstaWaWundanfrnu. {    XmungeinnigbeinaYvtillandlknisogLyfjastofnunaraWkannasrstaklegahvort sF eitthvaW;eWlilegtsseyWivarWandikynningar,vsanirognotkunmethylphenidats.Notk > uninborinsamanviWnotkunannarraYj;WavekurleitnarspurningarsemsvaraverWur.